Measuring the burden of childhood blindness

Globally, the prevalence of blindness among children is estimated to be approximately one tenth of that in adults, at around 0.7 per 1000. However, blindness in childhood has far reaching implications for the affected child and family, and throughout life profoundly influences educational, employment, personal, and social prospects. Thus, the control of childhood blindness has been identified as a priority of the World Health Organisation’s (WHO) global initiative for the elimination of avoidable blindness by the year 2020.

Measures of disease frequency alone, however, afford a limited understanding of the public health significance of childhood blindness. The global financial cost of blindness with an onset during childhood, in terms of loss of earning capacity (per capita GNP), is greater than the cost of adult blindness and has recently been estimated to be between US$6000 million and $27 000 million. Most of this is accounted for by children living in high income countries, where the prevalence is less, but life expectancy and earning capacity greater, than in low income countries. These financial costs alone, however, provide only one perspective of the public health burden of blindness. Improved understanding and quantification require the application of indicators which measure the impact of blindness in terms of morbidity (years of disability suffered) as well as mortality (years of life lost through premature blindness associated death). Such indicators are useful in identifying those in the population in greatest need and for setting priorities in provision of health services. They are also important in the assessment of effectiveness of interventions and their economic evaluation. Finally, they offer a means of prioritising the agenda for future research.

The use of composite measures of morbidity and mortality, together with epidemiological and demographic indicators of the burden of disease, is well known in international public health. However, there is considerable disagreement about the most appropriate measures and the methods used to derive them. Indeed, some have advised that the use of these composite measures be reconsidered on the basis that health status and burden of disease cannot be expressed in a single figure. An attempt has been made to measure the burden of visual impairment and blindness in adults in the Global Burden of Disease Study, which has attracted attention recently. The primary indicator of burden of disease, specifically developed for this study, was the time based outcome measure of disability adjusted life years (DALY) which is similar to the quality adjusted life year (QALY). Blindness was categorised, by expert consensus, in the penultimate class of increasingly severe disability. Cataaract, glaucoma, trachoma, and onchocerciasis were implicated, either directly or as risk factors for other disorders, in 3.1% of deaths worldwide and were estimated to result in 1.9% of global DALYs lost. By comparison, diabetes mellitus, implicated in 5.5% of deaths, accounted for the same percentage of DALYs. The potential for estimating the burden of childhood blindness from this study is limited by the categorisation of the major causes of blindness in children within other groups of disorders such as malnutrition, communicable diseases, perinatal disorders, and congenital anomalies. Nevertheless, the cost effective-
industrialised nations where the likely causes are so different. The problem of defining and measuring the disability or handicap resulting from visual impairment in childhood is challenging and, among other approaches, it will be necessary to develop visual outcome measures, including quality of life, which can be used in children of different ages. The findings of these areas of research have wide implications for practice and policy.

Thus, with our present knowledge it is difficult to estimate, with any certainty, the burden of childhood blindness in terms of morbidity and mortality. As up to 70% of childhood blindness worldwide might be effectively avoided by currently available primary, secondary, and tertiary preventive strategies, the need to improve existing strategies, especially in developing countries, as well as to develop new strategies, particularly in industrialised countries, to control childhood blindness is clear. However, given the economic considerations in healthcare provision in both settings, there is a need to demonstrate the relative value of these strategies to overall public health. Furthermore, there is a need to assess their effectiveness through their impact on the burden of disease. Thus we suggest that measuring the burden of childhood blindness accurately, as well as developing ways of effectively comparing it with other causes of morbidity, remain important goals.

Jugnoo Rahi was supported by a Medical Research Council clinical training fellowship during the preparation of this paper.

No special funding.

No conflict of interest.

J S RAHI

Department of Preventive Ophthalmology and Department of Ophthalmology, Institute of Child Health/Great Ormond Street Hospital and Institute of Ophthalmology, 30 Guilford Street, London WC1N 1EH

C E GILBERT

Department of Preventive Ophthalmology, Department of Infectious and Tropical Diseases, Institute of Ophthalmology, Bath Street, London EC1V 9EI

A FOSTER

London School of Hygiene and Tropical Medicine, 30 Keppel Street, London WC1E 7HT

D MNASSIAN

Department of Preventive Ophthalmology, Institute of Ophthalmology, Bath Street, London EC1V 9EI

Measuring the burden of childhood blindness

J S RAHI, C E GILBERT, A FOSTER and D MINASSIAN

Br J Ophthalmol 1999 83: 387-388
doi: 10.1136/bjo.83.4.387

Updated information and services can be found at:
http://bjo.bmj.com/content/83/4/387

These include:

References
This article cites 11 articles, 2 of which you can access for free at:
http://bjo.bmj.com/content/83/4/387#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/